|
FREE FATTY ACIDS AND HEPATIC ACTIVITY IN TYPE 2 DIABETES
Šaćira Mandal
Pages: 90-94
DOI: 10.21175/RadProc.2020.19
Abstract |
References | Cite This | Full Text (PDF)
Metabolic derangements in Type 2 diabetes mellitus (T2D) are associated primarily with the carbohydrate and lipid levels disturbances. Increased flow of free fatty acids (FFAs) into the blood that is coming from the adipocytes as well as an elevated flux of FFAs from de novo lipid synthesis in the liver contribute to these metabolic disturbances. Previous studies suggested a strong association of the hepatic activity of certain enzymes, such as aspartate and alanine transferase (AST, ALT), gamma glutamyl transpeptidase (GGT), and alkaline phosphatase (ALP) with the progression of T2D. In this study, the potential association of the hepatic activities of the liver enzymes and FFAs levels in T2D was examined. Analysis of the activities of ALT, AST, GGT and AP, as well levels of FFAs, fasting plasma glucose (FPG), and lipid profile was performed in 40 healthy control and 71 diabetic subjects. All participants were free of hepatitis, viral infections or active liver damage. The results showed a positive association between levels of palmitic and oleic acids with ALT activity (p<0.05), while the activity of GGT was significantly associated with the levels of palmitic, stearic, and oleic fatty acids (p<0.01). Interestingly, in control group, a positive correlation was found between palmitoleic acid levels with ALT activity (p<0.05), and a negative correlation palmitoleic acid with ALP activity (p<0.05) was observed. Obtained data suggest that an elevation of free fatty acid levels and the hepatic fat accumulation in insulin-resistant conditions affect the hepatic enzymes activities, which might contribute further to the progression of Type 2 diabetes and its complications.
-
IDF. International Diabetes Federation. IDF Diabetes Atlas — 9th Edition.
Diabetes Atlas.
Retrieved from:
https://diabetesatlas.org/resources/2017-atlas.html
Retrieved on: Sep. 17, 2020
-
P. J. Randle, P. B. Garland, C. N. Hales,
E. A. Newsholme, “The glucose fatty-acid cycle its role in insulin
sensitivity and the metabolic disturbances of diabetes mellitus,” Lancet, vol. 281, no. 7285,
pp. 785 –789, Apr. 1963.
DOI: 10.1016/s0140-6736(63)91500-9
PMid: 13990765
-
M. Hawkins, J. Tonelli, P. Kishore, D. Stein, E. Ragucci, A. Gitig, K.
Reddy, “Contribution of elevated free fatty acid levels to the lack of
glucose effectiveness in type 2 diabetes,” Diabetes, vol. 52, no.
11, pp. 2748 – 2758, Nov. 2003.
DOI: 10.2337/diabetes.52.11.2748
PMid: 14578293
-
J. A. Menendez, A. Vazquez-Martin, F. Jose Ortega,
J. M. Fernandez-Real, “Fatty acid synthase: association with insulin
resistance, type 2 diabetes, and cancer,” Clin. Chem., vol. 55,
no. 3, pp. 425 – 438, Jan. 2009.
DOI: 10.1373/clinchem.2008.115352
PMid: 19181734
-
S. Jiang, J. L. Young, K. Wang, Y. Qian, L. Cai, “Diabetic induced
alterations in hepatic glucose and lipid metabolism: The role of type 1 and
type 2 diabetes mellitus,” Mol. Med. Rep., vol. 22, no.2, pp. 603
–611, Aug. 2020.
DOI: 10.3892/mmr.2020.11175
PMid: 32468027
-
J. Zhang, N. Cheng, Y. Ma, H. Li, Z. Cheng, Y. Yang, et al., “Liver
enzymes, fatty liver and type 2 diabetes mellitus in a Jinchang cohort: a
prospective study in adults,” Can. J. Diabetes, vol. 42, no. 6,
pp. 652–658, Dec. 2018.
DOI: 10.1016/j.jcjd.2018.02.002
PMid: 29936075
-
S. Nagaraj, S. S. Kiran, R. Gandham, W. D. C. R. Silvia, M. R. Nagaraja, A.
S.Nasar, D. Biswajit, “Study of prevalence of non-alcoholic fatty liver
disease in type 2 diabetes mellitus patients and variations in liver
function tests, lipid profile and mean platelet volume in patients with
fatty liver in comparison with patients without fatty liver,” Int. J. Res.
Med. Sci., vol. 4, no. 3, pp. 871– 876, Mar. 2016.
DOI: 10.18203/2320-6012.ijrms20160534
PMid: 603
-
X.-Y. Hu, Y. Li, L.-Q. Li, Y. Zheng, J.-H. Lv,
S.-C. Huang, W. Zhang, L. Liu, L. Zhao, Z. Liu,
X.-J. Zhao, “Risk factors and biomarkers of nonalcoholic fatty liver
disease: an observational cross-sectional population survey,” BMJ Open, vol. 8, no. 4, pp. 1 – 7, Apr. 2018.
DOI: 10.3978/j.issn.2304-3881.2015.01.03
PMid: 29626047
-
H. B. Bhatt, R. J. Smith, “Fatty liver disease in diabetes mellitus,”
HepatoBiliary Surg. Nutr., vol. 4, no. 2,
pp. 101 – 108, Apr. 2015.
DOI: 10.2337/diabetes.52.11.2748
PMid: 26005676
-
F. Bril, K. Cusi, “Management of nonalcoholic fatty liver disease in
patients with type 2 diabetes: A call to action,” Diabetes Care,
vol. 40, no. 3, pp. 419 – 430, Mar. 2017.
DOI: 10.2337/dc16-1787
PMid: 28223446
-
K.L. Donnelly, C. I. Smith, S. J. Schwarzenberg,
J. Jessurun, M. D. Boldt, E. J. Parks, “Sources of fatty acids stored in
liver and secreted via lipoproteins in patients with nonalcoholic fatty
liver disease,” J. Clin. Invest., vol. 115, no. 5, pp. 1343 –
1351, May 2005.
DOI: 10.1172/JCI23621
PMid: 15864352
-
S. Islam, S. Rahman, T. Haque, A. H. Sumon,
A. M. Ahmed, N. Ali, “Prevalence of elevated liver enzymes and its
association with type 2 diabetes: A cross-sectional study in Bangladeshi
adults,” Endocrinol. Diabetes Metab., vol. 3, no.2, e00116,
Apr. 2020.
DOI: 10.1002/edm2.116
PMid: 32318634
-
D. M. Tanase, E. M. Gosav, C. F. Costea, M. Ciocoiu,
C. M. Lacatusu, M. A. Maranduca, A. Ouatu, M. Floria, “The intricate
relationship between type 2 diabetes mellitus (T2DM), insulin resistance
(IR), and nonalcoholic fatty liver disease (NAFLD)”, Journal of Diabetes Research, vol. 2020, Article ID 3920196,
p. 16, Aug. 2020.
DOI: 10.1155/2020/3920196
PMid: 343446834
-
M. T. Long, S. Gandhi, R. Loomba, “Advances in non-invasive biomarkers for
the diagnosis and monitoring of non-alcoholic fatty liver disease”, Metabolism,
vol. 111, pp. 154259-1-8, Oct. 2020.
DOI: 10.1016/j.metabol.2020.154259
PMid: 32387227
-
Association AD. 4, Comprehensive Medical Evaluation and Assessment of
Comorbidities: Standards of Medical Care in Diabetes-2019, Diabetes Care, vol. 42 (Suppl 1), pp. S34-S45, 2019.
DOI: 10.2337/dc19-S004
-
American Diabetes Association 2. Classification and Diagnosis of Diabetes:
Standards of Medical Care in Diabetes-2018, Diabetes Care, vol. 41
(Suppl 1),
pp. S13-S27, 2018.
-
Ethical principles for medical research involving Human Subjects
, World Medical Association, Helsinki, Finland, 1964.
Retrieved from:
https://www.who.int/bulletin/archives/79(4)373.pdf
Retrieved on: Sep. 17, 2020
-
R. Feng, C. Luo, C. Li, S. Du, A. P. Okekunle, Y. Li,
Y. Chen, T. Zi, Y. Niu, “Free fatty acids profile among lean, overweight
and obese non-alcoholic fatty liver disease patients: a case – control
study,” Lipids in Health and Disease, vol. 16, no. 165, pp. 1-9,
Sep. 2017.
DOI: 10.1186/s12944-017-0551-1
PMid: 28870233
-
T. Shibabaw, G. Dessie, M. D. Molla, M. F. Zerihun,
B. Ayelign, “Assessment of liver marker enzymes and its association with
type 2 diabetes mellitus in Northwest Ethiopia,” BMC. Res. Notes.,
vol. 12, no. 707, pp. 1– 5, Oct. 2019.
DOI: 10.1186/s13104-019-4742-x
PMid: 204940234
-
F. Imamura, A. M. Fretts, M. Marklund, A. V. Ardisson Korat, W.-S. Yang, M.
Lankinen, et al., “Fatty acids in the de novo lipogenesis pathway and
incidence of type 2 diabetes: A pooled analysis of prospective cohort
studies,” PLoS Med., vol. 17, no. 6, pp. e1003102–1-7, Jun. 2020.
DOI: 10.1371/journal. pmed.1003102
PMid: 32530938
-
T. K. Lam, A. Carpentier, G. F. Lewis, G. van de Werve, I. G. Fantus, A.
Giacca, “Mechanisms of the free fatty acid-induced increase in hepatic
glucose production,” Am. J. Physiol. Endocrino. Metab., vol. 284,
no. 5,
pp. E863–73. May 2003.
DOI: 10.1152/ajpendo.00033.2003
PMid: 12676648
-
H. R. Ahn, M. H. Shin, H. S. Nam, K.-S. Park,
Y.–H. Lee, S.-K. Jeong, “The association between liver enzymes and risk of
type 2 diabetes: The Namwon study,” Diabetol. Metab. Syndr., vol.
6, no. 1, p. 14,
Feb. 2014.
DOI: 10.1186/1758-5996-6-14
PMid: 24502834
-
S.-H. Ko, M. K. Baeg, K.-D. Han, S.-H. Ko, Y.-B. Ahn, “Increased liver
markers are associated with higher risk of type 2 diabetes,” World J. Gastroenterol., vol. 21,
no. 24, pp. 7478–87, June 2015.
DOI: 10.3748/wjg.v21.i24.7478
PMid: 26139993
-
S. Tomah, N. Alkhouri, O Hamdy, “Nonalcoholic fatty liver disease and type
2 diabetes: where do Diabetologists stand?”, Clin. Diabetes Endocrinol.,
vol. 6, no. 9, pp. 1–12, June 2020.
DOI: 10.1186/s40842-020-00097-1
PMid: 32518675
-
M. Akheruzzaman, V. Hegde, A. C. Shin,
N. V. Dhurandhar, “Reducing endogenous insulin is linked with protection
against hepatic steatosis in mice,” Nutr. Diabetes, vol. 10, no.
1, pp. 1–12,
Apr. 2020.
DOI: 10.1038/s41387-020-0114-9
PMid: 32286259
|